Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Kilitch Drugs (India) Ltd Performance

Today's Low
325.05
arrowIcon
Today's High
342.60
52 Wk Low
175.00
arrowIcon
52 Wk High
470.00


Open

339.7

Traded Value (Cr)

12.20 L

Prev. Close

327.55

VWAP

336.23

Volume

5,588

Face Value

10

Kilitch Drugs (India) Ltd Fundamentals

Market Cap
₹ 533 Cr
P/E Ratio (TTM)
36.59
P/B Ratio
3.18
Debt to Equity
0.17
ROE
8.38 %
EPS (TTM)
9.06
Dividend Yield
0.00%
Book Value
104.10

Click here to know more about Fundamentals

Kilitch Drugs (India) Ltd Financials

Kilitch Drugs (India) Ltd Financials

Kilitch Drugs (India) Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 69.23 % 69.23 % 69.23 % 68.25 %
Retail 25.37 % 26.13 % 26.13 % 27.40 %
Others 5.39 % 4.64 % 4.63 % 4.36 %
FII 0.00 % 0.00 % 0.00 % 0.00 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

69.23%

Retail

25.37%

Others

5.39%

FII

0.00%

Mutual Funds

0.00%

Promoters

69.23%

Retail

26.13%

Others

4.64%

FII

0.00%

Mutual Funds

0.00%

Promoters

69.23%

Retail

26.13%

Others

4.63%

FII

0.00%

Mutual Funds

0.00%

Promoters

68.25%

Retail

27.40%

Others

4.36%

FII

0.00%

Mutual Funds

0.00%

Resistance and Support

₹335.32

PIVOT

resistance-arrow
Resistance
First Resistance₹343.433
Second Resistance₹354.767
Third Resistance₹362.883
support-arrow
Support
First Resistance₹323.983
Second Resistance₹315.867
Third Resistance₹304.533
RSI36.337
MACD-6.221
ADX31.549
CCI-211.470

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day5,5884,58081.96
Week4,3762,79363.78
1 Month7,5974,78964.71
6 Months5,5913,80167.98

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Limited (KDIL) was incorporated in May, 1992 as a public limited company. The Company is a pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions. The Company went public in Feb.'94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.'95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions - O T C and ethical. A Pharmaceutical formulation plant at Sana'a Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with Al-Fath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America. The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5-cr tanning unit, which was implemented in the year 1995-96. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middle-east, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clue-plus, Bon-Bon Gripe Water and Kilitch Balm. The Company launched a new product 'BENIN' in the market in 2011. During the year 2011-12, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.

Managing Director

Mukund P Mehta

Founded

1992

NSE Symbol

KILITCH

Kilitch Drugs (India) Ltd Management

NameDesignation
Mukund P MehtaManaging Director
Bhavin M MehtaWhole-time Director
Hemang EngineerIndependent Director
Mira Bhavin MehtaWhole-time Director
Murti Vasudev KrishnaIndependent Director
Venkita Subramanian RajanIndependent Director
Pushpa NyoupaneCompany Sec. & Compli. Officer

Kilitch Drugs (India) Ltd News

Kilitch Drugs (India) consolidated net profit rises 22.78% in the December 2023 quarter
Sales rise 6.07% to Rs 31.79 crore
Kilitch Drugs (India) to conduct board meeting
On 8 February 2024
Kilitch Drugs (India) consolidated net profit rises 95.06% in the September 2023 quarter
Sales rise 34.20% to Rs 41.20 crore
Kilitch Drugs (India) to declare Quarterly Result
On 9 November 2023
Kilitch Drugs (India) schedules AGM
On 29 September 2023
Kilitch Drugs (India) consolidated net profit rises 60.77% in the June 2023 quarter
Sales rise 9.30% to Rs 36.56 crore
Kilitch Drugs (India) to convene board meeting
On 11 August 2023
Kilitch Drugs (India) to conduct board meeting
On 22 July 2023
Kilitch Drugs (India) consolidated net profit rises 22.76% in the March 2023 quarter
Sales rise 24.23% to Rs 45.48 crore
Kilitch Drugs (India) to table results
On 29 May 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,61,471 Cr
₹ 1,506.55
(0.80 %)
87.73
CIPLA₹ 1,08,154 Cr
₹ 1,339.55
(-1.42 %)
29.12
DIVISLAB₹ 1,00,705 Cr
₹ 3,793.50
(0.09 %)
73.80
ZYDUSLIFE₹ 98,827 Cr
₹ 982.15
(1.44 %)
36.80
DRREDDY₹ 98,773 Cr
₹ 5,921.00
(0.74 %)
22.73

Kilitch Drugs (India) Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Kilitch Drugs (India) Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Kilitch Drugs (India) Ltd's share price is ₹330.55 as of May 10, 2024

Kilitch Drugs (India) Ltd's P/E ratio is 36.59 times as of May 10, 2024.

Kilitch Drugs (India) Ltd's most recent financial reports indicate a price-to-book ratio of 3.18, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Kilitch Drugs (India) Ltd's market is 533 Cr as on May 10, 2024.

The current financial records of Kilitch Drugs (India) Ltd show a 8.38% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Kilitch Drugs (India) Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Kilitch Drugs (India) Ltd's 52-week high and low as of May 10, 2024 are ₹342.6 and ₹325.05 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Kilitch Drugs (India) Ltd stands at 69.23%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 0.00% to 0.00%.